Skip to content

Advertisement

  • Case report
  • Open Access
  • Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy

  • 1Email author,
  • 2,
  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 1,
  • 3 and
  • 1
BMC Infectious DiseasesBMC series – open, inclusive and trusted201717:478

https://doi.org/10.1186/s12879-017-2571-x

Received: 6 March 2017

Accepted: 27 June 2017

Published: 7 July 2017

Abstract

Background

Leishmaniasis is a protozoan disease caused by parasites of the genus Leishmania, transmitted to humans by sandflies. The diagnosis of leishmaniasis is often challenging as it mimics many other infectious or malignant diseases. The disease can present in three ways: cutaneous, mucocutaneous, or visceral leishmaniasis, which rarely occur together or consecutively.

Case presentation

The patient was a 52 years old immunosuppressed Belgian woman with a long history of severe rheumatoid arthritis. She underwent bone marrow biopsy to explore thrombocytopenia. Diagnosis of visceral leishmaniasis was made by identification of Leishman Donovan (LD) bodies in macrophages. Treatment with liposomal amphotericin B was successful. She later developed cutaneous leishmaniasis treated with amphotericin B lipid complex. She next presented with relapsing cutaneous lesions followed by rapidly progressing lymphadenopathies. Biopsy confirmed the diagnosis of leishmaniasis. Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate were subsequently initiated. She later presented a recurrent bone marrow involvement treated with intramuscular paromomycin and miltefosine. She died two years later from leukemia. At the time of death, she presented with a mucosal destruction of the nose. A Leishmania-specific PCR (Polymerase Chain Reaction) identified L. infantum as etiological agent.

Conclusions

Clinicians should be aware of the potential concomitant or sequential involvement of multiple anatomic localizations of Leishmania in immunosuppressed patients.

Keywords

  • Cutaneous leishmaniasis
  • Mucosal leishmaniasis
  • Visceral leishmaniasis
  • Immunosuppression
  • Parasitology
  • Microbiology

Background

Leishmaniasis is a protozoan disease caused by more than 20 species of the genus Leishmania and transmitted to humans by the bite of sandflies. The diagnosis of leishmaniasis is often challenging as it mimics many other infectious or malignant diseases.

Three patterns of infection are described: cutaneous (CL), mucosal (ML) and visceral leishmaniasis (VL). CL usually presents as papules, plaques, ulcers or nodules and occurs mostly on exposed areas of the skin. ML is characterized by destructive lesions mainly affecting the nose and the mouth. VL, also known as kala-azar or black fever, is a potentially fatal disease. Symptoms include fever, weight loss, hepato- and splenomegaly. Anemia and thrombocytopenia occur when parasites accumulate in the bone marrow. VL widely predominates in poor rural and suburban areas of India, Bangladesh, Sudan, Ethiopia and Brazil while CL is more broadly distributed and occurs in the south and central American countries, the Mediterranean basin, and from the Middle East to Central Asia [1]. ML is mostly observed in Latin America.

L. infantum is well recognized as the etiological agent of VL in southern Europe and is much less commonly reported as a cause of CL [2]. Mucosal forms of L. infantum infection are very rare [35]. Concomitant or consecutive cutaneous or mucosal with visceral clinical manifestations of leishmaniasis have been seldom described. Herein we report the first case of an immunosuppressed woman who presented the entire spectrum of the disease and we discuss its clinical significance.

Case presentation

The patient was a Belgian woman born in 1956 with a long history of severe rheumatoid arthritis (RA) complicated by vasculitis and cryoglobulinemia, and treated with etanercept, ciclosporin and methylprednisolone. She had only travelled to Spain in 2004.

In 2006 she developed mild anemia, thrombocytopenia and splenomegaly which were interpreted as manifestations of Felty syndrome. Screening for infectious diseases including HIV was negative. In March 2007 she was diagnosed with stage IIB EBV-negative classical Hodgkin lymphoma, based on an inguinal lymph node biopsy. The patient was treated with four cycles of C-MOPP (cyclophosphamide, vincristine, procarbazine and prednisone) plus radiation therapy targeting the left inguinal region. While undergoing chemotherapy she had persistent neutropenia (neutrophils: 1390/mm3, norm: 2100–8000/mm3) thrombocytopenia (thrombocytes: 43,000/mm3, norm: 170,000–400,000/mm3) and increasing splenomegaly. The markedly enlarged spleen (850 g) was surgically removed and showed marked histiocytic infiltrate of the red pulp, hemophagocytosis, and reactive polytypic plasma cells. Since thrombocytopenia was still increasing, she underwent bone marrow biopsy and aspirate in 2008. Diagnosis of VL was made by identification of Leishman Donovan (LD) bodies in macrophages after Giemsa staining (Fig. 1a). Serum antibody tests (indirect immunofluorescence) were positive for L. braziliensis, L. infantum and L. tropica due to cross reactions between species. In retrospect, Leishmania was also detected in the splenic sections (Fig. 1b).
Figure 1
Fig. 1

Visceral and cutaneous leishmaniasis. a. Bone marrow aspirate: May Grunwald Giemsa (original magnification: ×1000) showing two macrophages with abundant cytoplasm containing innumerable Leishmania amastigotes. b. Spleen histology: High power view of the splenic red pulp comprising a prominent infiltrate of histiocytes and plasma cells; the histiocytes show numerous cytoplasmic punctate bodies surrounded by a clear halo, suggestive of Leishman bodies (hematoxylin eosin staining; original magnification: ×400). c. Cutaneous histology: Diffuse infiltrate in the upper dermis consisting of predominantly large histiocytes, plasma cells and a few lymphocytes. Protozoan leishmania, visualized as multiple gray-blue bodies within the vacuolated cytoplasm of histiocytes (hematoxylin eosin staining)

Treatment with liposomal amphotericin B (4 mg/kg for 10 days) was successful. Due to immunosuppression, secondary prophylaxis with monthly amphotericin B was given as proposed for patients with HIV coinfection [6], but stopped after only 2 doses because of medical costs issues.

In 2009, etanercept treatment was replaced by rituximab twice a year. She developed multiple cutaneous nodular lesions mainly located in the left elbow and the buttocks. Histopathology was performed. LD bodies were evident within macrophages (Fig. 1c). Amphotericin B lipid complex treatment (5 mg/kg for 10 days) allowed for complete healing of the lesions. Secondary prophylaxis with monthly amphotericin B was again given. In 2010, despite secondary prophylaxis, she presented with relapsing cutaneous lesions followed by rapidly progressing lymphadenopathies (cervical, subclavicular, sub- and sus-diaphragmatic) on PET/CT. Lymph node biopsy showed massive macrophagic infiltrate comprising LD bodies. Rituximab was stopped. Treatment by miltefosine (50 mg bd) was instituted but then stopped because of digestive intolerance. Amphotericin B was reintroduced but failed, probably because of resistance. N-methyl-glucamine antimoniate (20 mg/kg), more recently used with success by other groups when multiple failures or relapses occur after treatment with liposomal amphotericin B [7], was subsequently initiated and then stopped after the patient experienced torsade de pointes. Cutaneous lesions disappeared and PET/CT showed an almost full metabolic response with disappearance of adenopathy. However, she later presented thrombocytopenia due to recurrent bone marrow involvement which was successfully treated with intramuscular paromomycin (15 mg/kg) and miltefosine (50 mg bd) for 28 days.

In 2012, she presented few relapsing cutaneous lesions requiring topical treatment. Two years later she was diagnosed with chronic myelomonocytic leukemia and died in 2015 from blastic crisis. At the time of death, she presented with a mucosal destruction of the nose clearly visible on a CT scan performed a few days before she died (Fig. 2). Autopsy was performed to confirm the mucosal involvement by Leishmania. A real-time Leishmania-specific PCR [8] performed on the nasal biopsy was positive (cycle threshold value 23,87) and molecular HSP70-typing identified L. infantum as etiological agent [9].
Figure 2
Fig. 2

Mucosal leishmaniasis. CT scan showing left maxillary sinusitis and centimetric perforation of the nasal septal cartilage

Discussion and conclusion

L. infantum is the etiological agent of VL in Europe where it is endemic in the Mediterranean region. Dogs are considered the major reservoir and sandflies are the only proven vectors of this zoonotic protozoan disease [10]. The incidence of VL associated with the transmission of L. infantum has been declining in many foci where living standards have improved. Immunosuppression confers a higher risk of clinical disease due to L. infantum. While visceral and cutaneous manifestations of L. infantum are quite common, mucosal presentation is rare and has been only sporadically described. Association of cutaneous and visceral involvement has been reported in patients co-infected with HIV [11]. Simultaneous mucosal and visceral manifestations have been described in corticosteroid-treated patients [12]. Interestingly, Souza et al. very recently reported patients from an endemic area of leishmaniasis, treated for RA, who presented with recurrent CL or ML [13]. However, we believe that this case report is the first example of L. infantum infection with recurrent visceral, cutaneous and finally mucosal involvement. The development of all these clinical manifestations has been facilitated by immunosuppressive therapy required to control a severe RA.

This case also demonstrates that the diagnosis of leishmaniasis is often challenging as it mimics many other infectious or malignant diseases. The scarcity of leishamniasis in non-endemic settings like Belgium makes the diagnosis even more difficult and contributed to the delay before diagnosis. Thrombocytopenia was first thought related to hypersplenism. Following splenectomy, persistent thrombocytopenia could be caused by numerous conditions and manifestations of VL are often misinterpreted as symptoms of malignancies, other infectious or autoimmune diseases such as systemic lupus erythematosus [14]. Discussion of cutaneous lesions is also challenging since CL mimics other infectious conditions including mycobacteriosis or inflammatory diseases such as nummular dermatitis or psoriasis. Moreover, cutaneous lesions could have been considered as post-kala-azar dermal leishmaniasis. However, the recurrence of cutaneous lesions together with VL relapse as well as the localized nature of the cutaneous lesions rather suggests CL. Diagnosis of mucosal lesions located in the nose is complex since lesions often mimic neoplastic processes or necrotizing vasculitis [15].

In conclusion, this exceptional case highlights that clinicians should be aware of the potential concomitant or sequential involvement of multiple anatomic localizations of leishmaniasis in immunosuppressed patients. This observation is particularly relevant given the risk of emergence of leishmaniasis in Europe consequent to the increasing worldwide travelling of humans and domestic dogs, increasing flow of migrants from the Middle East to Europe and climatic changes [16]. Indeed, the occurrence of sandflies in Central Europe and in adjacent regions of Western-Europe is established and sandflies have been found in several parts of Germany and Belgium [17]. Thus local acquisition of leishmaniasis in Belgium is not totally excluded.

Abbreviations

CL: 

Cutaneous leishmaniasis

C-MOPP: 

Cyclophosphamide, vincristine, procarbazine and prednisone

LD bodies: 

Leishman Donovan bodies

ML: 

Mucosal Leishmaniasis

PCR: 

Polymerase Chain Reaction

VL: 

Visceral leishmaniasis

Declarations

Acknowledgements

Not applicable.

Funding

The authors declare no competing financial interests. This work was supported by the Belgian Fund for Scientific Research (FRS-FNRS, Belgium).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

GD, JBG, MM and PL managed the patient. GVDA, MPH and LC performed and analyzed antibody testing and PCR. FT, LDL and JAE performed anatomo-pathological examination. All authors have been involved in drafting the manuscript as well as revising it critically for important intellectual content. All authors participated to literature search. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not Applicable.

Consent for publication

Consent to publish was obtained from a next-of-kin after the patient’s death.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Centre Hospitalier Universitaire (CHU) de Liège, Liège, Belgium
(2)
Institute of Tropical Medicine, Antwerp, Belgium
(3)
Service of clinical Pathology, Lausanne University Hospital, Lausanne, Switzerland

References

  1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.View ArticlePubMedPubMed CentralGoogle Scholar
  2. del Giudice P, Marty P, Lacour JP, Perrin C, Pratlong F, Haas H, et al. Cutaneous leishmaniasis due to Leishmania infantum. Case reports and literature review. Arch Dermatol. 1998;134:193–8.View ArticlePubMedGoogle Scholar
  3. Ramos A, Munez E, Garcia-Dominguez J, Martinez-Ruiz R, Chicharro C, Banos I, et al. Mucosal leishmaniasis mimicking squamous cell carcinoma in a liver transplant recipient. Transpl Infect Dis. 2015;17:488–92.View ArticlePubMedGoogle Scholar
  4. Jeziorski E, Dereure J, Mac Bullen G, Blanchet C, Ludwig C, Costes V, et al. Mucosal relapse of visceral leishmaniasis in a child treated with anti-TNFalpha. Int J Infect Dis. 2015;33:135–6.View ArticlePubMedGoogle Scholar
  5. Pampin Franco A, Gamo Villegas R, Caro-Gutierrez D, Lopez-Estebaranz JL, Pinedo F. Mucosal leishmaniasis of the tongue caused by Leishmania infantum in an immunocompetent woman. Int J Dermatol. 2015;54:e39–41.View ArticlePubMedGoogle Scholar
  6. Lopez-Velez R, Videla S, Marquez M, Boix V, Jimenez-Mejias ME, Gorgolas M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother. 2004;53:540–3.View ArticlePubMedGoogle Scholar
  7. Morizot G, Jouffroy R, Faye A, Chabert P, Belhouari K, Calin R, et al. Antimony to cure visceral Leishmaniasis unresponsive to liposomal Amphotericin B. PLoS Negl Trop Dis. 2016;10:e0004304.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Van Os L, Cnops L, Van Esbroeck M, Dhubhghaill SN, De Keizer RJ, Asselman V, et al. Slowly progressive Keratouveitis in a patient with known systemic Leishmaniasis and HIV. Ocul Immunol Inflamm. 2015;23:248–51.View ArticlePubMedGoogle Scholar
  9. Van der Auwera G, Maes I, De Doncker S, Ravel C, Cnops L, Van Esbroeck M, et al. Heat-shock protein 70 gene sequencing for Leishmania species typing in European tropical infectious disease clinics. Euro Surveill. 2013;18:20543.View ArticlePubMedGoogle Scholar
  10. Maia C, Cardoso L. Spread of Leishmania infantum in Europe with dog travelling. Vet Parasitol. 2015;213:2–11.View ArticlePubMedGoogle Scholar
  11. Postigo C, Llamas R, Zarco C, Rubio R, Pulido F, Costa JR, et al. Cutaneous lesions in patients with visceral leishmaniasis and HIV infection. J Inf Secur. 1997;35:265–8.Google Scholar
  12. Pittalis S, Nicastri E, Spinazzola F, Ghirga P, De Marco M, Paglia MG, et al. Leishmania infantum leishmaniasis in corticosteroid--treated patients. BMC Infect Dis. 2006;6:177.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Souza RM, Andrade HFJ, Duarte MI, Braz LM, Schubach AO, Silva FC, et al. Reactivation of cutaneous and mucocutaneous tegumentary leishmaniasis in rheumatoid arthritis patients: an emerging problem? Rev Inst Med Trop Sao Paulo. 2017;59:e6.PubMedPubMed CentralGoogle Scholar
  14. Santana IU, Dias B, Nunes EA, Rocha FA, Silva FS Jr, Santiago MB. Visceral leishmaniasis mimicking systemic lupus erythematosus: case series and a systematic literature review. Semin Arthritis Rheum. 2015;44:658–65.View ArticlePubMedGoogle Scholar
  15. Cobo F, Rodriguez-Granger J, Gomez-Camarasa C, Sampedro A, Aliaga-Martinez L, Navarro JM, et al. Localized mucosal leishmaniasis caused by Leishmania infantum mimicking cancer in the rhinolaryngeal region. Int J Infect Dis. 2016;50:54–6.View ArticlePubMedGoogle Scholar
  16. Ready PD. Leishmaniasis emergence in Europe. Euro Surveill. 2010;15:19505.PubMedGoogle Scholar
  17. Aspock H, Gerersdorfer T, Formayer H, Walochnik J. Sandflies and sandfly-borne infections of humans in Central Europe in the light of climate change. Wien Klin Wochenschr. 2008;120:24–9.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement